Ed Arce is a Managing Director of Equity Research at H.C. Wainwright with expertise in both the biopharmaceutical and the specialty pharmaceutical sectors. In particular, Mr. Arce’s research covers investment opportunities among hepatology, renal, infectious disease, gastrointestinal, endocrine, metabolic and select rare disease companies Mr. Arce has been involved in institutionally-focused healthcare research since 2005. Prior to joining H.C. Wainwright, Mr. Arce was a Senior Research Analyst at ROTH Capital Partners. Mr. Arce’s previous sell-side experience includes working for MLV & Co, Wedbush Securities, UBS Securities and First Albany Capital.
H. C. Wainwright & Co.
Analyst
H.C. Wainwright & Co. is one of the country’s oldest financial institutions. H.C. Wainwright & Co. was founded in 1868 at the Union Bank Building in Boston, Massachusetts, located at the heart of the strongest financial center in post-Civil War America. H.C. Wainwright & Co., is a full-service investment bank dedicated to providing corporate fiance, strategic and licensing advisory, research, sales & trading, and related services to pubic and private companies. H.C. Wainwright & Co. has been the leader in the CMPU (confidentially marketed public offerings), RD (registered direct offering) and PIPE (private investment in public equity) transactions since 1998.
